Contemporary Trends in Adjuvant and Neoadjuvant Treatment for Renal Cell Carcinoma
Journal Title: Üroonkoloji Bülteni - Year 2018, Vol 17, Issue 3
Abstract
Renal cell carcinoma is an increasingly significant cancer in which surgical resection is still the sole curative approach. There is a risk of recurrence in one-third of patients after surgery. Successful experiences with some solid organ cancers and effective treatment response to targeted agents in metastatic cases have suggested a similar adjuvant approach for renal cell carcinoma. Consequently, placebo-controlled adjuvant trials have been reported and the Food and Drug Administration approved sunutinib as an adjuvant treatment after nephrectomy in high-risk patients, with the risk of treatment-related side effects. Several clinical series have indicated that neoadjuvant application can provide significant downsizing of the cancer mass in complex cases and enable radical surgery. Similarly, neoadjuvant therapy could enable nephron-sparing surgery for certain patients. Both adjuvant and neoadjuvant approaches for renal cell carcinoma require further trials with larger patient numbers. This review presents contemporary experience on adjuvant and neoadjuvant treatment for renal cell carcinoma.
Authors and Affiliations
Kamil Çam
Keywords
Related Articles
- EP ID EP382524
- DOI 10.4274/uob.1030
- Views 105
- Downloads 0
A Rare Side Effect of Intravesical Bacillus Calmette-Guérin Therapy: Reactive Arthritis
Approximately 70-80% of bladder cancers are superficial tumors and not muscle invasive. Complete transurethral resection of the bladder tumour (TUR-BT) is the standard approach to these patients. Intravesical treatments...
The Clinical, Oncological, Functional and Surgical Outcomes of Patients Who Underwent Adrenalectomy
Objective: Adrenal masses are often benign and rarely malignant. They may be also hormonally functional or non-functional. It is possible to treat these masses curatively with open and laparoscopic adrenalectomy. The aim...
Synchronous and Metachronous Secondary Tumors of Bladder Cancer Patients
The improvements in cancer treatment prolonged survival in patients. Despite this survival benefit, chemotherapies, radiotherapies or combination therapies, and continuing exposure to the same carcinogenic agents may lea...
Impact of Delay from Biopsy to Surgery on the Rate of Adverse Pathologic and Oncologic Outcomes for Clinically Localized Prostate Cancer
Objective: Due to the widespread usage of prostate-specific antigen screening, the number of patients diagnosed with prostate cancer is steadily increasing. Many factors such as high operating room demand, insurance reim...
What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?
Objective: To detect a prostate-specific antigen (PSA) cut-off for clinically significant prostate cancer (csPCa) according to age in Turkey. Materials and Methods: A total of 532 men who had transrectal ultrasound-guid...